Molecular markers to individualize adjuvant therapy for colon cancer
Authors:
- 4 May 2010
- journal article
- review article
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 7 (6) , 318-325
Abstract
While many patients with early-stage colon cancer are cured with surgery alone, the standard of care remains a uniform approach to adjuvant chemotherapy based primarily on tumor stage. Recently, increasing awareness of the need for more individualized decision-making in cancer care has led to the development of several potential prognostic and predictive markers in colon cancer. While adjuvant chemotherapy with 5-fluorouracil, leucovorin and oxaliplatin is clearly beneficial to patients with stage III disease, well-validated molecular markers might help define which patients with stage II disease are likely to benefit from adjuvant therapy as well. Here, we review the data on the clinical development of molecular markers to individualize adjuvant therapy in colon cancer.Keywords
This publication has 68 references indexed in Scilit:
- Molecular Basis of Colorectal CancerNew England Journal of Medicine, 2009
- KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803Clinical Cancer Research, 2009
- Aspirin Use and Survival After Diagnosis of Colorectal CancerJAMA, 2009
- Association of GUCY2C Expression in Lymph Nodes With Time to Recurrence and Disease-Free Survival in pN0 Colorectal CancerJAMA, 2009
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal CancerNew England Journal of Medicine, 2008
- Racial and Ethnic Differences in Advance Care Planning Among Patients With Cancer: Impact of Terminal Illness Acknowledgment, Religiousness, and Treatment PreferencesJournal of Clinical Oncology, 2008
- Survival Following Recurrence in Stage II and III Colon Cancer: Findings From the ACCENT Data SetJournal of Clinical Oncology, 2008
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III StudyJournal of Clinical Oncology, 2008
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- Chromosome 17 Deletions and p53 Gene Mutations in Colorectal CarcinomasScience, 1989